Overview
Bifeprunox in the Treatment of Schizophrenia
Status:
Completed
Completed
Trial end date:
2008-01-01
2008-01-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
Study of the long-term efficacy and safety of bifeprunox in the treatment of schizophrenia. Extension to study S154.3.001.Phase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Solvay Pharmaceuticals
Criteria
Inclusion Criteria:diagnosis of schizophrenia, understand nature of study, able to be managed in out-patient
setting for long-term bifeprunox treatment
Exclusion Criteria:
current primary diagnosis other than schizophrenia, suicide risk, diagnosis or history of
substance abuse, uncontrolled hypertension